Literature DB >> 22516290

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.

Debbie Zittema1, Wendy E Boertien, André P van Beek, Robin P F Dullaart, Casper F M Franssen, Paul E de Jong, Esther Meijer, Ron T Gansevoort.   

Abstract

BACKGROUND AND OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary renal disease, characterized by cyst formation in the kidneys leading to end stage kidney failure. It is clinically acknowledged that ADPKD patients have impaired urine concentrating capacity, but the mechanism behind this observation is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifteen ADPKD patients (estimated GFR ≥60 ml/min per 1.73 m(2)) and 15 age- and sex-matched healthy controls underwent a standard prolonged water deprivation test in which urine and plasma osmolality, vasopressin, and copeptin were measured. The effect of a synthetic vasopressin analog (desmopressin) injected at the moment of maximal urine concentrating capacity was also studied.
RESULTS: After 14 hours of water deprivation, ADPKD patients tended to have higher plasma osmolality (P=0.07) and significantly higher vasopressin and copeptin levels (both P<0.05), whereas urine osmolality was similar in ADPKD patients and controls (710 versus 742 mOsmol/kg; P=0.61). Maximal urine concentrating capacity was lower in ADPKD patients (758 versus 915 mOsmol/kg in controls; P<0.001). At maximal urine concentrating capacity, plasma osmolality, vasopressin, and copeptin levels were significantly higher in ADPKD patients. The median increase in urine osmolality after desmopressin administration in ADPKD patients was less than in healthy controls.
CONCLUSIONS: Already early in their disease, ADPKD patients have impaired maximal urine concentrating capacity brought out upon dehydration, with no evidence of impaired hypothalamic response. To maintain fluid balance, vasopressin concentration increases, which is hypothesized to play a role in ADPKD disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516290     DOI: 10.2215/CJN.11311111

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  40 in total

1.  Hyponatremia and cyst growth in neonatal polycystic kidney disease: a case for aquaretics?

Authors:  Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2017-02-13       Impact factor: 3.714

2.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

3.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

4.  Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD.

Authors:  Lise Bankir; Daniel G Bichet
Journal:  Nat Rev Nephrol       Date:  2012-06-26       Impact factor: 28.314

5.  Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.

Authors:  Osama W Amro; Jessica K Paulus; Farzad Noubary; Ronald D Perrone
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

Review 6.  Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Authors:  Markus M Rinschen; Bernhard Schermer; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

7.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

Review 8.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

9.  Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Authors:  Debbie Zittema; Else van den Berg; Esther Meijer; Wendy E Boertien; Anneke C Muller Kobold; Casper F M Franssen; Paul E de Jong; Stephan J L Bakker; Gerjan Navis; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

Review 10.  Dysnatremias in patients with kidney disease.

Authors:  Sara Combs; Tomas Berl
Journal:  Am J Kidney Dis       Date:  2013-11-14       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.